R-enantiomer beta-2 agonists for inflammatory bowel disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) are ineffective and associated with significant adverse effects, lacking a safe and well-tolerated therapy with rapid onset and long-term remission capabilities, and existing medications often induce serious side effects.
Innovation Solution
The use of R-enantiomers of adrenergic β2 receptor agonists, such as R-salbutamol, R-bambuterol, and R-clenbuterol, either alone or in combination with anti-inflammatory or immunosuppressant drugs, to treat IBD and its extra-intestinal manifestations, demonstrating superior efficacy and reduced toxicity compared to their S-enantiomers or racemic forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If racemic forms or S-enantiomers of β2 receptor agonists are used for treatment of IBD, then the therapeutic coverage is broader, but the adverse effects and disease exacerbation increase
Solution Approach 1:
The patent segments the racemic mixture into separate enantiomers (R and S), isolating the therapeutically beneficial R-enantiomer from the harmful S-enantiomer. This segmentation allows selective use of the R-enantiomer's anti-inflammatory properties while eliminating the S-enantiomer's disease-exacerbating effects, thus resolving the contradiction between broad therapeutic coverage and adverse effects
Solution Approach 2:
The patent extracts and isolates the R-enantiomer from the racemic mixture, removing the harmful S-enantiomer component. This extraction process enables the use of pure R-enantiomer formulations that provide therapeutic benefits without the harmful effects associated with S-enantiomers, directly addressing the contradiction between versatility and harmful factors
2Duration of action of stationary object
If long-term treatment with conventional IBD medications is administered, then disease symptoms are controlled, but serious adverse effects are induced
Solution Approach 1:
The patent changes the chemical parameter of the drug formulation by using pure R-enantiomer instead of racemic mixture or S-enantiomer. This parameter change (enantiomeric purity) maintains therapeutic efficacy for long-term disease control while eliminating the harmful effects that limit long-term use of conventional medications
3Device complexity
If S-enantiomer of β2 receptor agonists is used for IBD treatment, then the drug structure is simpler, but the disease symptoms are exacerbated
Solution Approach 1:
The patent inverts the conventional approach by selecting the R-enantiomer instead of the S-enantiomer or racemic mixture. This inversion reveals that the previously overlooked R-enantiomer is the therapeutically active component, while the S-enantiomer causes disease exacerbation, thus resolving the contradiction between structural simplicity and harmful effects
Data Source
AI summary
This invention disclosed a new use of optically pure R-enantiomer of adrenergic β2 agonists including R-salbutamol, R-terbutaline, R-clenbuterol and R-bambuterol for treatment of inflammatory bowel disease and its extra intestinal manifestations including skin diseases.